University of Iowa Hospitals and Clinics
Research Study to Investigate the Effects of a Common Anti-inflammatory Drug on Blood Vessel and Heart Function
Healthy, non-smoking adults age 50-79 years are invited to participate in a research study to test the effects of the drug salsalate (similar to aspirin) to test blood vessel and heart function. Your involvement will include; blood draws, 24 hour blood pressure monitoring, surveys, and tests of blood vessel function. Compensation will be provided. For details, please contact Veronica Howsare (319) 467-5677 or email email@example.com.
The lead investigator at the University of Iowa is Gary L. Pierce, PhD, Assistant Professor, Health Human Physiology.
Veronica Howsare: (319) 467-5677
Aspire A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso®(Treprostinil) Inhalation Solution
Primary Outcome Measures: Describe the type and incidence of oro-/nasopharyngeal and pulmonary adverse events that may be associated with current or recent treatment with Tyvaso for PAH and with patients not treated with Tyvaso for PAH.
Please refer to www.clinicaltrials.gov for more information identifier NCT01266265
Pulmonary Hypertension Program
Cynthia Larew RN 319-356-1028 pager # 2123
The purpose of this study is to demonstrate that the results achieved in the original pivotal clinical investigation of 81 subjects from five clinical sites are generalizable to new clinical sites that complete the staff training defined in the SynCardia Systems, Inc. Training Manual and who enroll subjects who meet the intended use defined in the product Instructions for Use.
Please refer to www.clinicaltrials.gov identifier NCT00614510 for more information.
Cardiomyopathy Treatment Program
Page Scovel, RN
This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).
Please refer to www.clinicaltrials.gov identifier NCT01457781 for further information.
The purposes of this study are to confirm that the Freedom Driver System is a suitable pneumatic driver for clinically stable TAH-t subjects, and that patients and lay caregivers can be trained to manage the Freedom Driver System safely outside the hospital.
Please refer to www.clinicaltrials.gov identifier NCT00733447 for more information.
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.